부산대학교 도서관

All CMV DNAemia episodes cleared spontaneously, and no patients developed either recurrent CMV DNAemia or CMV end-organ disease within the study period. Enumeration of cytomegalovirus (CMV)-specific CD8+ and CD4+ T cells in patients undergoing treatment with ibrutinib either with or without detectable CMV DNAemia. Keywords: CMV; CMV DNAemia; CMV CD8+ T cells; CMV CD4+ T cells; chronic lymphocytic leukaemia; ibrutinib EN CMV CMV DNAemia CMV CD8+ T cells CMV CD4+ T cells chronic lymphocytic leukaemia ibrutinib 637 641 5 11/18/21 20211115 NES 211115 Ibrutinib has become standard of care for treatment of high-risk and relapsed refractory chronic lymphocytic leukaemia (CLL).1 Ibrutinib targets Bruton tyrosine kinase (BTK), which plays a major role in B- and T-cell proliferation and survival2 and recognition of infectious agents by the innate immune system.3 Ibrutinib therapy has been associated with an increased incidence of several opportunistic infections, especially in the first 6-12 months after therapy initiation,4-7 among which cytomegalovirus (CMV) end-organ disease has been anecdotally reported.8 Nevertheless, little is known about the biology of CMV in ibrutinib-treated patients. Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib. [Extracted from the article]